Effects of galectin-9 on systemic lupus erythematosus or similar inflammatory diseases

A galectin, systemic technology, applied in the field of biomedicine, can solve the problem of no research report on the effect of galectin-9, etc.

Inactive Publication Date: 2014-03-12
SHANGHAI BIRDIE BIOTECH INC
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0025] The current study is limited to mice with autoimmune diabetes, mice with inflammatory bowel disease, animal models of multiple sclerosis with experimental autoimmune encephalomyelitis, and clinical cases in peripheral blood and There have also been preliminary studies on tumor cells in vitro, but there is no report on the role of galectin-9 in SLE diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Effects of galectin-9 on systemic lupus erythematosus or similar inflammatory diseases
  • Effects of galectin-9 on systemic lupus erythematosus or similar inflammatory diseases
  • Effects of galectin-9 on systemic lupus erythematosus or similar inflammatory diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0061] Example 1 Expression of recombinant human galectin-9 (Gal-9) protein:

[0062] Through the method of chemical synthesis, design and synthesize the sequence of recombinant human Gal-9 protein gene (SEQ ID No: 2), the sequence includes length Ala2-Thr323 total 322AA, (NCBI Accession#BAA31542), the front end is added to the expression vector Not I restriction site, 6 His (used for affinity chromatography, combined with nickel column to reduce purification steps) and EK restriction site, including stop codon TAA, and KpNI restriction enzyme for cloning The linker is 9bp in total.

[0063] The recombinant human Gal-9 protein gene monomer was excised with restriction endonucleases Not I and KpNI, connected to the vector pET32a digested with Not I and KpN I, transformed into E. coli, and screened for ampicillin-resistant transformants child. After plasmid extraction, restriction enzyme digestion identification proved that the recombinant human Gal-9 protein gene monomer has been ...

Embodiment 2

[0066] Example 2 Cultivation of human plasmacytoid dendritic cells and the study of affecting the secretion of type I interferon in plasmacytoid dendritic cells

[0067] Materials and Method:

[0068] R848 (1μg / mL) (purchased from InvivoGen, San Diego, CA)

[0069] CpG typeA oligodeoxynucleotide chain (2216, 5μM), type B (2006, 5μM), type C (C274, 5μM)

[0070] γ-irradiated herpes simplex virus (HSV)-1 (KOS strain; 10PFU / cell)

[0071] Influenza virus (PR8strain; 10PFU / cell)

[0072] Sendai virus (Cantellstrain; 5PFU / cell)

[0073] Recombinant Galectin-1 (purchased from R&D Systems, Minneapolis, MN)

[0074] Recombinant human GM-CSF (100ng / mL, purchased from R&D Systems, Minneapolis, MN)

[0075] Recombinant human IL-4 (200ng / mL, purchased from R&D Systems, Minneapolis, MN)

[0076] IFN-α ELISA kit (PBL, Biomedical Laboratories, Piscataway, NJ)

[0077] Human CD14 beads (purchased from Miltenyi Biotec, Auburn, CA)

[0078] BDCA4+ separation kit (purchased from Miltenyi Biotec, Auburn, CA)

[00...

Embodiment 3

[0091] Example 3 Study on the inhibitory effect of galectin-9 on the secretion of type I interferon in plasmacytoid dendritic cells

[0092] Materials and Method:

[0093] R848 (1μg / mL) (purchased from InvivoGen, San Diego, CA)

[0094] CpG typeA oligodeoxynucleotide chain (2216, 5μM), type B (2006, 5μM), type C (C274, 5μM)

[0095] γ-irradiated herpes simplex virus (HSV)-1 (KOS strain; 10PFU / cell)

[0096] Influenza virus (PR8strain; 10PFU / cell)

[0097] Sendai virus (Cantellstrain; 5PFU / cell)

[0098] Reorganization of Galectin-1 (R&D Systems, Minneapolis, MN)

[0099] Recombinant human GM-CSF (100ng / mL, purchased from R&D Systems, Minneapolis, MN)

[0100] Recombinant human IL-4 (200ng / mL, purchased from R&D Systems, Minneapolis, MN)

[0101] IFN-α ELISA kit (PBL, Biomedical Laboratories, Piscataway, NJ)

[0102] Human CD14 beads (purchased from Miltenyi Biotec, Auburn, CA)

[0103] BDCA4+ separation kit (purchased from Miltenyi Biotec, Auburn, CA)

[0104] Anti-human CD123-PE, anti-human CD...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to view more

Abstract

The invention relates to application of galectin-9, an active derivative thereof or a pharmaceutically acceptable salt thereof in preparation of drugs used for treating systemic lupus erythematosus or similar inflammatory diseases. The invention provides a method for treating systematic autoimmune diseases. The method comprises a step of administrating a therapeutically effective amount of galectin-9, the active derivative thereof or the pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier to an object to be treated, and a systematic autoimmune disease is effectively treated or alleviated.

Description

Technical field [0001] The invention belongs to the field of biomedicine. Specifically, the present invention relates to the use of galectin-9 or its active derivatives, or pharmaceutically acceptable salts thereof, for the preparation of drugs for the treatment of systemic autoimmune diseases. The systemic autoimmune diseases include systemic lupus erythematosus diseases or inflammatory diseases with similar mechanisms. Background technique [0002] Systemic lupus erythematosus disease (SLE) is a prototype systemic autoimmune disease. Guidelines for the diagnosis and treatment of systemic lupus erythematosus in adults (Guidelines for Referral and Management of Systemic Lupus Erythematosus in Adults, Arthritis Rheum 1999; 42:1785) point out that the disease includes systemic symptoms and disorders, musculoskeletal, skin, kidney, gastrointestinal system, and respiratory system , Cardiovascular system, reticuloendothelial tissue, blood and nervous system have disease. Among them...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61P37/02A61P29/00
Inventor 李立新
Owner SHANGHAI BIRDIE BIOTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap